
13. References

- Acocella, G., Nicolis, F.B., Lamarina, A., 1967. A study of the kinetics of rifampicin in man. *Chemotherapia*, 5, 87.
- Alam, M.A., Al-Jenoobi, F.I., Al-Mohizea, A.M., 2011. Everted gut sac model as a tool in pharmaceutical research: limitations and applications. *J. Pharm. Pharmacol.*, 64, 326–336.
- Ali, J., Ali, N., Sultana, Y., Baboota, S., Faiyaz, S., 2007. Development and validation of a stability-indicating HPTLC method for analysis of antitubercular drugs. *Acta Chromatogr.*, 18, 168-179.
- Baka, E., Comer, J.E.A, Krisztina, T.N, 2008. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. *J. Pharm. Biomed. Anal.* 46, 335–341.
- Blomberg, B., Spinaci, S., Fourie, B., Laing, R., 2001. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. *Bulletin of the World Health Organization*, 79(1), 61-68.
- Brijesh, S., Dave, Avani, F., Amin, Patel, M.M., 2004. Gastroretentive drug delivery system of ranitidine hydrochloride: Formulation and in vitro evaluation. *AAPS PharmSciTech*, 5(2), 77-82.
- Dash, S., Murthy, P.N., Nath, L., Chowdhury. P., 2010. Kinetic modeling on drug release from controlled drug delivery systems, *Acta Pol.*, 67(3), 217-223.
- Dhalleine, C., Assifaoui, A., Moulari, B., Pellequer, Y., Cayot, P., Lamprecht, A., Chambin, O., 2011. Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. *Int. J. Pharm.*, 414(1-2), 28-34.
- DOTS-Plus Guidelines, 2010. Revised National Tuberculosis Control Programme.
- Eldeen, A., Yassin, B., Alsarra, I.A., Al-Mohizea, A.M., 2006. Chitosan Beads as a New gastroretentive System of Verapamil. *Sci. Pharm.*, 74, 175-188.
- Examples of enteric coating processes for tablets, Degussa., Rohm Pharma Polymers.
- Flynn, J.L., John, C., 2001. Tuberculosis: Latency and reactivation. *Infect. Immun.*, 69(7), 4195–4201.
- Glass, B.D., Agatonovic, Kustrin, S., Chen, Y.J., Wisch, M.H., 2007. Optimization of a stability-indicating HPLC method for the simultaneous determination of rifampicin,

- isoniazid, and pyrazinamide in a fixed-dose combination using artificial neural networks. *J. Chromatogr. Sci.*, 45, 38-44.
- Gohel, M.C., Krishnakant, G.S., 2007. A novel solid dosage form of rifampicin and isoniazid with improved functionality. *AAPS PharmSciTech*, 8(3) Article 68.
- Gohel, M.C., Sarvaiya, K.G., 2008. Exploration of cold extrusion for the preparation of enteric minitablets of isoniazid. *Indian J. Pharm. Sci.*, 70(3), 298-302.
- Groning, R., Heun, G., 1984. Oral dosage forms with controlled gastrointestinal transit. *Drug Dev. Ind. Pharm.*, 10, 527–539.
- Gupta N.V., Gowda, D.V., Balamuralidhara, V., Khan S.M., 2011. Formulation and evaluation of olanzapine matrix pellets for controlled release. *Daru*, 19(4), 249-256.
- <http://en.wikipedia.org/wiki/Sphericity>
- <http://en.wikipedia.org/wiki/Tuberculosis>
- http://en.wikipedia.org/wiki/Tuberculosis_treatment
- http://en.wikipedia.org/wiki/Tuberculosis_diagnosis
- <http://www.drugbank.ca/drugs/DB01059>. Accessed on 20/09/13
- <http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html>. Downloaded on 9/4/13
- http://www.pharmacopoeia.cn/v29240/uspfnf24s0_c1174.html. Downloaded on 13/10/13
- Jagdale, S.C., Agavekar, A.J., Pandya, S.V., Kuchekar, B.S., Chabukswar, A.R., 2009. Formulation and evaluation of gastroretentive drug delivery system of propranolol hydrochloride. *AAPS PharmSciTech*, 10(3), 1071-1079.
- Jakko, van, I., Rob, E.A., Peter, R.D., Andreas, H.D, Rodney, D., Georgette, P., van, B., Stephen, H.G., Martin, J.B., 2013. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Downloaded from <http://cid.oxfordjournals.org/>
- Joshi, A., Pund, S., Nivsarkar, M., Vasu, K., Shishoo, C., 2007. Dissolution test for site-specific release isoniazid pellets in USP apparatus 3 (reciprocating cylinder): Optimization using response surface methodology. *Eur. J. Pharm. Biopharm.*, 69, 769–775.
- Kebrele, H., 1970. Physicochemical factors of drugs affecting absorption, distribution, and excretion. *Acta Pharma*. 30-47.

- Khuhawar, M.Y., Rind, F.M.A., 1998. High performance liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin in pharmaceutical preparations. *Pak. J. Pharm. Sci.*, 11(2), 49-54.
- Kumar, A.K.H., Chandra, I., Geetha, R., Chelvi, K.S., Lalitha, V., Prema, G., 2004. A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine. *Indian J. Pharmacol.*, 36(4), 231-233.
- Lachman, L., Lieberman, H.A, Kanig, L.J., 2009. *The Theory and Practice of Industrial Pharmacy*. Special Indian ed., CBS Publishers & Distributers Pvt. Ltd., New Delhi.
- Liebermann, H.A., Lachman, L., Schwartz, J.B., 1990. *Pharmaceutical Dosage Forms: Tablets*, Vol.2, Marcel Dekker, New York, pp. 201-243.
- Liu, J., Sun, J., Zhang, W., Gao, K., Zhonggui, H., 2008. HPLC determination of rifampicin and related compounds in pharmaceuticals using monolithic column. *J. Pharm. Biomed. Anal.*, 46, 405–409.
- Mariappan, T.T., Singh, S., 2003. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. *Int. J. Tuberc. Lung Dis.*, 7(8), 797-803.
- Microbiology Text Book, 2005. *Mycobacterium tuberculosis*. <http://www.bact.wisc.edu/MicrotextBook/modules.php?op=modload&name=Sections&file=index&req=viewarticle&artid=138>.
- Nahid, P., Madhukar, P., Philip, C., Hopewell, 2006. Advances in the diagnosis and treatment of Tuberculosis. *Proc. Am. Thorac. Soc.*, 3, 103–110.
- Panchagnula, R., Agrawal, S., 2004. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. *Int. J. Pharm.*, 271, 1–4.
- Patel, R.P., Baria, A.H., Pandya, N.B., 2009. Stomach-specific Drug Delivery of Famotidine using Floating Alginate beads. *Int. J. PharmTech Res.*, 1(2), 288-291.
- Petri, W.A., 2001. Antimicrobial Agents. In: Hardmann, J.G., Limbird, L.E., Gilman, A.G (Eds.) *The Goodman and Gilman's: The Pharmacological Basis of Therapeutics*. MacGraw Hill Medical Publishing Division, New York, 10th ed., pp. 1273-1294.
- Pharmaceutical Methods, General Chapters*, 2007, Volume 1, 5th ed., Indian Pharmacopoeia, Ministry of H & F, Govt. of India.

- Podczec, F.P. Alessi, J.M. Newton, 2008. The preparation of pellets containing non-ionic surfactants by extrusion/spheronization. *Int. J. Pharm.*, 361, 33–40.
- Pund, S., Joshi, A., Vasu, K., Nivsarkar, M., Shishoo, C., 2009. Multivariate optimization of formulation and process variables influencing physico-mechanical characteristics of site-specific release isoniazid pellets. *Int. J. Pharm.*, 388(1), 64-72.
- Reagents and solutions, General Chapters, 2007, Volume 1, 5th ed., Indian Pharmacopoeia, Ministry of H & F, Govt. of India.
- Reagents and solutions, General Chapters, 2010, Volume 1, 6th ed., Indian Pharmacopoeia, Ministry of H & F, Govt. of India.
- Robitzek, E.H., Selikoff, I.J., 1952. Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report. *Am. Rev. Tuberc.*, 65(4), 402-428.
- Sandler, N., Rantanen, J., Heincamcaki, J., Rcomer, M., Marvola, M., Yliruusil, J., 2005. Pellet manufacturing by extrusion-spheronization using process analytical technology. *AAPS PharmSciTech*, 6(2), Article 26, E174-E183.
- Sangeetha, S., Sakthisaravanan, V., Komala, M., Harish, G., Sivakumar, V., 2010. Design and evaluation of gastro-retentive beads of theophylline by ionotropic gelation. *Int. J. Pharm. Pharm. Sci.*, 2(3), 99-101.
- Sankar, R., Sharda, N., Singh, S., 2003. Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1–3. *Drug Dev. Ind. Pharm.*, 29(7), 733–738.
- Sarma, S.K., 1985. Cyclic motor activity: Migrating motor complex. *Gastroenterology*, 89, 894–913.
- Sensi, P., 1983. History of the development of rifampin. *Rev. Infect. Dis.*, 5(3), 402-406.
- Shishoo, C.J, Shah, S.A, Rathod, I.S, Savale, S.S, Kotecha, J.S, Shah, P.B, 2001. Stability of rifampicin in dissolution medium in presence of isoniazid. *Int. J. Pharm.*, 190, 109–123.
- Singh, S., Mariappan, T.T, Sankar, R, Sarda, N, Baljinder Singh, 2001. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. *Int. J. Pharm.*, 228, 5–17.

- Snyder, L.R., Kirkland, J.J., Glacjch, J.L., 1997. Practical HPLC method development. 2nd ed., Wiley-Interscience publication, John Wiley & Sons, Inc, USA.
- Stanley, S., Davis, 2005. Formulation strategies for absorption windows, *Drug Discov. Today*, 10.
- Suter, E., 1952. Multiplication of tubercle bacilli within phagocytes cultivated in vitro, and effect of streptomycin and isonicotinic acid hydrazide. *Am. Rev. Tuberc.*, 65(6), 775-776.
- Tekade, A.R., Gattani, S.G., 2010. Dual cross-linked pulsatile beads for chronotherapy of asthma: development and evaluation. *Drug Deliv.*, 17(8), 581-586.
- The United States Pharmacopoeia, USP 32. United States Pharmacopoeial Convention Inc., Rockville, Maryland, USA.
- Treatment of tuberculosis: Guidelines for national programmes, 2003. 3rd ed., World Health Organization.
- Treatment of tuberculosis: Guidelines, 2010. 4th ed., World Health Organization.
- Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control, 2011. TB (partial update) clinical guideline, NICE clinical guideline 117, Developed by the National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at National Institute for Health and Clinical Excellence.
- Vani, M., Meena, A., Savio, F.G., Priya, M., Nancy, 2010. Design and evaluation of gastro retentive floating beads of ranitidine hydrochloride. *Int J. Pharm. Biomed. Sci.*, 1(1), 1-4.
- Wade, M.M., Zhang Y., 2004. Mechanisms of drug resistance in mycobacterium tuberculosis. *Front. Biosci.*, 9, 975-994.
- Waldron, M., 2013. A practical guide to the extrusion and spheronization of pharmaceuticals using NICA™ System. GEA Pharma Systems, 1-26.
- Wehrli, W., Knüsel, F., Schmid, K., Staehelin M., 1968. Interaction of rifamycin with bacterial RNA polymerase. *Proc. Natl. Acad. Sci.*, 61, 667-673.
- Yellanki, S.K., Nerella, N.K., 2010. Stomach specific drug delivery of riboflavin using floating alginate beads, *Int. J. Pharm. Pharm. Sci.*, 2, 160-163.
- Zhang, Y., Heym, B., 1992. The catalase-peroxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*. *Nature*, 358(6387), 591-593.